Related references
Note: Only part of the references are listed.Combined inhibition of Chk1 and Wee1 In vitro synergistic effect translates to tumor growth inhibition in vivo
Laura Carrassa et al.
CELL CYCLE (2012)
WEE1 inhibition sensitizes osteosarcoma to radiotherapy
Jantine PosthumaDeBoer et al.
BMC CANCER (2011)
MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts
N. V. Rajeshkumar et al.
CLINICAL CANCER RESEARCH (2011)
WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
Philip C. De Witt Hamer et al.
CLINICAL CANCER RESEARCH (2011)
MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
Kathleen A. Bridges et al.
CLINICAL CANCER RESEARCH (2011)
Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease
Raquel Dominguez-Kelly et al.
JOURNAL OF CELL BIOLOGY (2011)
Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Timothy J. Guzi et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Single-Agent Inhibition of Chk1 Is Antiproliferative in Human Cancer Cell Lines In Vitro and Inhibits Tumor Xenograft Growth In Vivo
Kurtis D. Davies et al.
ONCOLOGY RESEARCH (2011)
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
Cynthia X. Ma et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase
Halfdan Beck et al.
JOURNAL OF CELL BIOLOGY (2010)
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
David Parry et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Chk1 promotes replication fork progression by controlling replication initiation
Eva Petermann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets
Elizabeth Iorns et al.
PLOS ONE (2009)
Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors
Zhan Xiao et al.
BIOMARKERS (2008)
Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase
E Petermann et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Fhit and CHK1 have opposing effects on homologous recombination repair
BC Hu et al.
CANCER RESEARCH (2005)
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
CS Sorensen et al.
NATURE CELL BIOLOGY (2005)
Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase
A Krämer et al.
NATURE CELL BIOLOGY (2004)
Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A
CS Sorensen et al.
CANCER CELL (2003)
Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints
H Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing
C Feijoo et al.
JOURNAL OF CELL BIOLOGY (2001)
Share Paper
